RAPT Therapeutics, Inc.
NASDAQ:RAPT
3.1 (USD) • At close November 7, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
| Revenue
| 0 | 1.527 | 3.813 | 5.042 | 0 | 0 | 0 |
| Cost of Revenue
| 3.551 | 2.807 | 0.996 | 0 | 1.33 | 1.237 | 1.384 |
| Gross Profit
| -3.551 | -1.28 | 2.817 | 5.042 | -1.33 | -1.237 | -1.384 |
| Gross Profit Ratio
| 0 | -0.838 | 0.739 | 1 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 101.002 | 67.082 | 56.985 | 45.485 | 34.91 | 31.767 | 25.618 |
| General & Administrative Expenses
| 26.06 | 20.24 | 16.037 | 12.771 | 8.719 | 5.18 | 3.713 |
| Selling & Marketing Expenses
| -3.551 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 26.06 | 20.24 | 16.037 | 12.771 | 8.719 | 5.18 | 3.713 |
| Other Expenses
| 0 | 1.957 | 0.005 | 1.312 | 1.292 | 0.8 | 0.216 |
| Operating Expenses
| 127.062 | 87.322 | 73.022 | 58.256 | 43.629 | 36.947 | 29.331 |
| Operating Income
| -127.062 | -85.795 | -69.209 | -53.214 | -43.629 | -36.947 | -29.331 |
| Operating Income Ratio
| 0 | -56.185 | -18.151 | -10.554 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| 10.264 | 1.957 | 0.005 | 1.312 | 1.292 | 0.8 | 0.216 |
| Income Before Tax
| -116.798 | -83.838 | -69.204 | -51.902 | -42.337 | -36.147 | -29.115 |
| Income Before Tax Ratio
| 0 | -54.904 | -18.149 | -10.294 | 0 | 0 | 0 |
| Income Tax Expense
| 0 | -1.957 | -0.996 | 0.99 | 0.66 | 0.8 | 0 |
| Net Income
| -116.798 | -81.881 | -68.208 | -52.892 | -42.997 | -36.147 | -29.115 |
| Net Income Ratio
| 0 | -53.622 | -17.888 | -10.49 | 0 | 0 | 0 |
| EPS
| -3.05 | -2.52 | -2.49 | -2.19 | -1.97 | -2.09 | -2.01 |
| EPS Diluted
| -3.05 | -2.52 | -2.49 | -2.19 | -1.97 | -2.09 | -2.01 |
| EBITDA
| -125.846 | -85.795 | -69.209 | -53.214 | -43.629 | -35.71 | -27.947 |
| EBITDA Ratio
| 0 | -56.185 | -18.151 | -10.554 | 0 | 0 | 0 |